Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04CRL
|
|||
| Former ID |
DAP001315
|
|||
| Drug Name |
Glatiramer Acetate
|
|||
| Synonyms |
Glatiramer acetate; Copaxone; 147245-92-9; Copolymer 1; Copolymer-1; COP-1; Protiramer; Glatopa; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); (2S)-2,6-diaminohexanoic acid; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; AC1MIXQC; 5M691HL4BO
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Approved | [1], [2] | |
| Therapeutic Class |
Immunosuppressive Agents
|
|||
| Company |
Teva Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H45N5O13
|
|||
| Canonical SMILES |
CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N
|
|||
| InChI |
1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
|
|||
| InChIKey |
FHEAIOHRHQGZPC-KIWGSFCNSA-N
|
|||
| CAS Number |
CAS 147245-92-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3335, 422198, 476220, 584062, 584557, 587335, 819231, 821124, 821317, 821460, 821464, 821466, 821467, 821468, 821469, 821471, 821473, 821475, 821477, 821479, 821481, 821483, 821522, 821685, 823364, 823659, 823684, 823783, 824287, 824663, 825112, 825309, 825310, 825585, 826374, 826935, 827238, 827899, 830759, 831816, 831825, 831826, 831832, 831965, 832015, 833751, 833822, 833839, 834163, 834730
|
|||
| ADReCS Drug ID | BADD_D01020 ; BADD_D01021 | |||
| SuperDrug ATC ID |
L03AX13
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class II antigen DRB1*1 (HLA-DRB1) | Target Info | Binder | [3] |
| Pathway Interaction Database | TCR signaling in naï | |||
| IL12-mediated signaling events | ||||
| CXCR4-mediated signaling events | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Phosphorylation of CD3 and TCR zeta chains | |||
| Translocation of ZAP-70 to Immunological synapse | ||||
| Generation of second messenger molecules | ||||
| MHC class II antigen presentation | ||||
| PD-1 signaling | ||||
| Interferon gamma signaling | ||||
| WikiPathways | MHC class II antigen presentation | |||
| TCR signaling | ||||
| Interferon gamma signaling | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1058). | |||
| REF 2 | The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother. 2009 Mar;10(4):657-68. | |||
| REF 3 | Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.